Disability progression among leprosy patients released from treatment: a survival analysis
- PMID: 32448360
- PMCID: PMC7245886
- DOI: 10.1186/s40249-020-00669-4
Disability progression among leprosy patients released from treatment: a survival analysis
Abstract
Background: Leprosy can be cured, but physical disability (PD) as a result of the infection can progress in the post-release from treatment phase. This study evaluated the likelihood of, and factors associated with, the progression of the PD grade post-release from treatment among leprosy patients treated in Cáceres-MT, Brazil in the period 2000 to 2017.
Methods: A retrospective cohort study and survival analysis were performed in the hyperendemic municipality of Cáceres in the state of Mato Grosso. The study population consisted of newly diagnosed leprosy patients released from treatment between January 1, 2000 and December 31, 2017. The main outcome was the progression of the PD grade with regard to probability and time; and the evaluated covariates included clinical, operational and demographic variables. The Cox proportional risk model was used to estimate the risk ratio (Hazard Ratios) of the covariates. Both an univariate and a multivariate analysis were implemented, with 95% confidence intervals.
Results: The mean time for progression of the PD grade was 162 months for PB and 151 months for MB leprosy patients. The survival curve showed that 15 years after the release from treatment, the probability of PD grade progression was 35%, with no difference between PB and MB or age groups. Leprosy reactions and registered medical complaints of any kind during treatment were identified as risk factors with Hazard Ratios of 1.6 and 1.8 respectively.
Conclusions: People released from treatment as cured of leprosy are susceptible to worsening of the PD, especially those who have had complications during multi-drug therapy treatment. This indicates that leprosy patients should be periodically monitored, even after the successful completion of multidrug therapy.
Keywords: Cure; Leprosy; Physical disability; Progression; Survival.
Conflict of interest statement
The authors declare they have no competing interests.
Figures


Similar articles
-
Progression of leprosy disability after discharge: is multidrug therapy enough?Trop Med Int Health. 2013 Sep;18(9):1145-1153. doi: 10.1111/tmi.12156. Trop Med Int Health. 2013. PMID: 23937704 Free PMC article.
-
Perception of cure among leprosy patients post completion of multi-drug therapy.BMC Infect Dis. 2021 Sep 6;21(1):916. doi: 10.1186/s12879-021-06587-6. BMC Infect Dis. 2021. PMID: 34488660 Free PMC article.
-
Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients.PLoS Negl Trop Dis. 2017 Jul 13;11(7):e0005725. doi: 10.1371/journal.pntd.0005725. eCollection 2017 Jul. PLoS Negl Trop Dis. 2017. PMID: 28704363 Free PMC article. Clinical Trial.
-
[Leprosy-related disabilities after release from multidrug treatment: prevalence and spatial distribution].Rev Saude Publica. 2012 Dec;46(6):969-77. doi: 10.1590/s0034-89102013005000002. Epub 2013 Jan 28. Rev Saude Publica. 2012. PMID: 23358621 Portuguese.
-
Individual and community factors determining delayed leprosy case detection: A systematic review.PLoS Negl Trop Dis. 2021 Aug 12;15(8):e0009651. doi: 10.1371/journal.pntd.0009651. eCollection 2021 Aug. PLoS Negl Trop Dis. 2021. PMID: 34383768 Free PMC article.
Cited by
-
Dermlep Study Part 3: Post-RFT Events in Leprosy Patients Presenting to Dermatologists.Indian Dermatol Online J. 2022 May 5;13(3):340-345. doi: 10.4103/idoj.idoj_683_21. eCollection 2022 May-Jun. Indian Dermatol Online J. 2022. PMID: 36226023 Free PMC article.
-
Risk Factors for Disability Upgrading Among Leprosy Patients During Treatment: Multilevel Modeling Analysis.SAGE Open Nurs. 2022 Oct 9;8:23779608221129936. doi: 10.1177/23779608221129936. eCollection 2022 Jan-Dec. SAGE Open Nurs. 2022. PMID: 36238938 Free PMC article.
-
Clinical and radiological evaluation of maxillofacial and otorhinolaryngological manifestations of Hansen's disease.Sci Rep. 2022 Sep 1;12(1):14912. doi: 10.1038/s41598-022-19072-0. Sci Rep. 2022. PMID: 36050504 Free PMC article.
-
Experiences of living with leprosy: A systematic review and qualitative evidence synthesis.PLoS Negl Trop Dis. 2022 Oct 5;16(10):e0010761. doi: 10.1371/journal.pntd.0010761. eCollection 2022 Oct. PLoS Negl Trop Dis. 2022. PMID: 36197928 Free PMC article.
-
A review of nutrition in neuropathic pain of leprosy.Ther Adv Infect Dis. 2022 Jun 1;9:20499361221102663. doi: 10.1177/20499361221102663. eCollection 2022 Jan-Dec. Ther Adv Infect Dis. 2022. PMID: 35677111 Free PMC article. Review.
References
-
- Withington SG, Joha S, Baird D, Brink M, Brink J. Assessing socio-economic factors in relation to stigmatization, impairment status, and selection for socio-economic rehabilitation: a 1-year cohort of new leprosy cases in North Bangladesh. Lepr Rev. 2003;74(2):120–132. - PubMed
-
- Barbosa JC, Ramos Junior AN, Alencar OM, Pinto MSP, Castro CGJ. Leprosy after release from treatment in the Brazilian unified health system: aspects for access in the northeast region. Cad Saúde Colet. 2014;22(4):351–358. doi: 10.1590/1414-462X201400040008. - DOI
-
- Costa LG, Cortela D, Soares RC, Ignotti E. Factors associated with the worsening of the disability grade during leprosy treatment in Brazil. Lepr Rev. 2015;86:265–272. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous